Expression of herstatin, an alternative HER-2/NEU product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth

Details for Australian Patent Application No. 2001286483 (hide)

Owner Oregon Health and Science University

Inventors Clinton, Gail M

Agent Davies Collison Cave

Pub. Number AU-B-2001286483

PCT Pub. Number WO02/14470

Priority 09/638,834 14.08.00 US

Filing date 14 August 2001

Wipo publication date 25 February 2002

Acceptance publication date 15 May 2008

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 35/00 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C07K 16/32 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

22 April 2004 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 05 Jun 2003 2002

15 May 2008 Application Accepted

  Published as AU-B-2001286483

11 September 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001286484

2001286482